ImmunID Strengthens its Intellectual Property Position with the Issuance of a Key Technology Patent in China

GRENOBLE, France, Dec. 14, 2015 /PRNewswire/ -- ImmunID, the immune companion diagnostics company, today announced the granting of a key patent in China. This patent (WO 2009095567) covers the multi-N-plex® Polymerase Chain Reaction (PCR) technology underlying the ImmunTraCkeR® and ImmunIG® assays. ImmunTraCkeR® and ImmunIG® evaluate a patient's own immune status, based on T cell repertoire diversity and B cell repertoire diversity, respectively. ImmunTraCkeR® has demonstrated clinical utility predicting response to cancer immunotherapy and is currently under further validation in the Predict-ID program for prediction of response and monitoring of cancer patients under treatment with immune checkpoint inhibitors.

Photo - http://photos.prnewswire.com/prnh/20151211/295195

"This new granted patent strengthens our IP position in immune diagnostics worldwide. ImmunID's patent portfolio consists of 35 patents covering its technology platform and clinical applications in and outside the field of immuno-oncology in Europe, the United States, Japan, and now, China as well. Our ImmunTraCkeR® assay enables a more precise immune monitoring of cancer patients and we are establishing it as a major immune companion diagnostics for immune checkpoint agents and other cancer immunotherapies," said Dr. Nicolas Pasqual, Chief Scientific Officer and Co-Founder of ImmunID.

About ImmunID
ImmunID adds precision to the immuno-oncology revolution by personalizing immunotherapy for cancer patients. With its decade-long experience in immune molecular diagnostics, ImmunID provide doctors with clinically meaningful data on the highly complex immune system to select the right therapy for individual patients and to monitor their response. ImmunID's flagship CE-marked product, ImmunTraCkeR®, evaluates the patient's immune status based on the T lymphocyte diversity, from a simple liquid biopsy. The company is establishing ImmunTraCkeR® as the general immune companion diagnostic assay for immune checkpoint inhibitors and other immunotherapies. In addition, ImmunID collaborates with pharma and biotech companies to optimize the development of their next-generation immunotherapies. ImmunID is ISO 9001 and ISO 13485 certified and runs a CAP-accredited laboratory in the MINATEC high-tech campus in Grenoble, France.

www.immunid.com - Follow ImmunID on Twitter: @ImmunID

About ImmunTraCkeR^®
ImmunTraCkeR^® is a proprietary CE-marked immune molecular diagnostics assay, which evaluates a patient's immune status in the blood based on combinatorial T cell diversity. Unlike most companion diagnostics tests, ImmunTraCkeR^® is patient-specific rather than drug- or disease-specific, as it approaches the disease from the patient's own immune system perspective. ImmunTraCkeR^® provides information on the patient's complex immune profile to evaluate clinical benefit or risk under treatment with immunotherapies. ImmunTraCkeR^® may ultimately be used as immune companion diagnostics and answer the urgent medical need for efficient patient stratification tools in melanoma and other solid cancers.

Contact
Bernhard Sixt
Chairman and CEO
Email
Phone: +33 438 785 770

SOURCE ImmunID

Related Links

http://www.immunid.com